Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Todd C. Brady
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Beta
- 1.19
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -10.68
Financials
Revenue
$0.00-100.0%Net Income
$-5.45MEBITDA
$-5.38MFree Cash Flow
$-4.61MEPS (diluted)
$-0.09Shares Outstanding (diluted)
60.32M+383.5%Operating Expenses
$5.85MCash & Debt
$45.09MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-33.85M | $-0.56 |
| 2024 | $0.00 | $-55.85M | $-0.94 |
| 2023 | $0.00 | $-37.54M | $-0.64 |
| 2022 | $0.00 | $-62.02M | $-1.06 |
| 2021 | $0.00 | $-57.78M | $-1.07 |
| 2020 | $0.00 | $-37.55M | $-1.11 |
| 2019 | $0.00 | $-60.83M | $-2.24 |
| 2018 | $0.00 | $-38.89M | $-1.79 |
| 2017 | $0.00 | $-22.34M | $-1.40 |
| 2016 | $0.00 | $-18.70M | $-1.65 |
| 2015 | $0.00 | $-12.09M | $-1.40 |
| 2014 | $0.00 | $-5.19M | $-1.36 |
| 2013 | $0.00 | $13.06M | $39.90 |
| 2012 | $0.00 | $-23.07M | $-146.63 |
Valuation
ALDXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
153+1433.33%Social Signal Score
Mentions (4)
- Newsbenzinga.com·6d ago·Positive
Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares are trading higher on Tuesday as investors react to the company's intent to submit a formal dispute resolution request tied to its reproxalap program.
View source ↗ - Newsseekingalpha.com·6d ago·Positive
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript
View source ↗ - Newsmarketbeat.com·6d ago·Negative
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease Aldeyra Therapeutics NASDAQ: ALDX said it plans to submit a formal dispute resolution request, or FDRR, to the FDA's Office of New Drugs seeking review of the agency's latest complete response letter for reproxalap, its investigational treatment for the signs and symptoms of dry eye disease.
View source ↗ - Newsbusinesswire.com·7d ago·Negative
Aldeyra Therapeutics to Host Regulatory Update Webcast CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the company will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET. The update will focus on reproxalap, an investigational drug for the treatment of dry eye disease. A live audio …
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.11 per share
Typical surprise +23.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.09 vs $-0.09miss
- Thu, May 7$-0.06 vs $-0.13beat
- Fri, Feb 27$-0.11 vs $-0.14beat
- Wed, Nov 5$-0.13 vs $-0.17beat
- Thu, Aug 7$-0.16 vs $-0.21beat
- Wed, May 14$-0.17 vs $-0.25beat
Estimates and results for ALDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALDX officers and directors.
- Bought
- $3.3m
- Sold
- $10.3m
11 trades
13 trades
- Brady Todd Cbought
- Douglas Richardbought
- Alfieri Michaelbought
- Alfieri Michaelbought
- Machatha Stephensold
- Perceptive Advisors Llcsold
- Machatha Stephensold
- Greenberg Brucesold
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ALDX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.